A Hybrid Biomaterial-biological Vector for Antigen Presenting Cell Gene Delivery

用于抗原呈递细胞基因传递的混合生物材料-生物载体

• 批准号: 7990629
• 负责人: Blaine Pfeifer
• 金额: $ 7.24万
• 依托单位: TUFTS UNIVERSITY MEDFORD
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-07-15 至 2011-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7990629
• 关键词: Antigen-Presenting Cells; Antigens; Bacteria; Bacterial Antigens; Biocompatible Materials; Biological; Biological Assay; Biological Products; Cells; Clinical; Communicable Diseases; Development; Devices; Disease model; Emerging Communicable Diseases; Engineering; Future; Gene Delivery; Grant; Hybrids; Immune response; In Vitro; Individual; Malignant Neoplasms; Medicine; Molecular Biology; Outcome; Pilot Projects; Polymer Chemistry; Process; Property; Research; Risk; Schools; Scientist; System; Technology; Testing; Therapeutic; Time; Vaccines; Virus; Vision; Work; bacterial vector; biocompatible polymer; biomaterial compatibility; design; engineering design; gene delivery process; genetic vaccine; hybrid gene; improved; innovation; novel; public health relevance; success; tool; vector

DESCRIPTION (provided by applicant): The proposed R03 pilot study will combine two traditional gene delivery vectors into a novel hybrid device with potential to surpass the gene delivery efficacy of either original vector. Biomaterials have been a primary vehicle to facilitate gene delivery due to their inherent biocompatibility and adjustable properties available to influence cellular delivery mechanisms. More recently, bacterial vectors have also been used for gene delivery and provide an orthogonal set of biological engineering parameters to further influence the cellular gene delivery process. In this work, a hybrid biomaterial-bacterial device will be generated that combines the best features of both individual vectors. More specifically, previous studies using either biomaterial or bacterial vectors for targeted antigen presenting cell gene delivery will now be combined in an effort to boost gene delivery efficacy to these particular cells. Improved gene delivery as a result of the new hybrid biomaterial- biological vectors will establish the technology as innovative. More importantly, the hybrid devices will provide a completely new platform for engineering design that includes disparate tools such as polymer chemistry and molecular biology to further modify and technically advance the potency of the vectors. This will be a key theme of future grant submissions as will be the application of the new devices, facilitated through established connections between Tufts' Schools of Engineering and Medicine, as genetic vaccines against infectious disease and cancer. PUBLIC HEALTH RELEVANCE: Success will provide two health-related outcomes: 1) a completely new gene delivery device with biological and biomaterial engineering tools available for future optimization and 2) a broad platform technology to be dedicated to new disease models and more advanced therapeutic applications.

描述（由申请人提供）：拟定的R 03初步研究将联合收割机两种传统基因递送载体组合成一种新型混合装置，该装置有可能超过任一原始载体的基因递送功效。生物材料由于其固有的生物相容性和可调节的特性而成为促进基因递送的主要载体，这些特性可影响细胞递送机制。最近，细菌载体也被用于基因递送，并提供了一组正交的生物工程参数，以进一步影响细胞基因递送过程。在这项工作中，将产生一种混合生物材料-细菌装置，它结合了两种载体的最佳特征。更具体地说，使用生物材料或细菌载体进行靶向抗原呈递细胞基因递送的先前研究现在将结合起来，以努力提高对这些特定细胞的基因递送功效。由于新的混合生物材料-生物载体的结果，改进的基因递送将确立该技术的创新性。更重要的是，混合设备将为工程设计提供一个全新的平台，包括不同的工具，如聚合物化学和分子生物学，以进一步修改和技术上提高载体的效力。这将是未来拨款申请的一个关键主题，新设备的应用也将是如此，通过塔夫茨工程学院和医学院之间建立的联系，作为预防传染病和癌症的基因疫苗。 公共卫生相关性：成功将提供两个与健康相关的成果：1）一个全新的基因递送装置，具有可用于未来优化的生物和生物材料工程工具，2）一个广泛的平台技术，致力于新的疾病模型和更先进的治疗应用。